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Abstract
Background: Physician-led home visit care with medical teams (Zaitaku care) has been developed on a national
scale to support those who wish to stay at home at the end of life, and promote a system of community-based
integrated care in Japan. Medical care at the end of life can be expensive, and is an urgent socioeconomic issue for
aging societies. However medical costs of physician-led home visits care have not been well studied. We compared
the medical costs of Zaitaku care and hospital care at the end of life in a rapidly aging community in a rural area in
Japan.
Methods: A cross-sectional study was performed to compare the total medical costs during patients’ final days of
life (30 days or less) between Zaitaku care and hospital care from September 2012 to August 2013 in Fukuoka
Prefecture, Japan.
Results: Thirty four patients died at home under Zaitaku care, and 72 patients died in the hospital during this
period. The average daily cost of care during the last 30 days did not differ significantly between the two groups.
Although Zaitaku care costs were higher than hospital care costs in the short-term (≦10 days, Zaitaku care $371.2
vs. Hospital care $202.0, p = 0.492), medical costs for Zaitaku care in the long-term care (≧30 days) were less than
that of hospital care ($155.8 vs. $187.4, p = 0.055).
Conclusions: Medical costs of Zaitaku care were less compared with hospital care if incorporated early for long
term care, but it was high if incorporated late for short term care. For long term care, medical costs for Zaitaku care
was 16.7% less than for hospitalization at the end of life. This physician-led home visit care model should be an
available option for patients who wish to die at home, and may be beneficial financially over time.
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Background
By 2050, the population of elderly people (those over
65 years of age) is expected to grow to 38.8% in Japan,
37.4% in Korea, 36.4% in Spain, 24.1% in United
Kingdom (U.K.) and 21% in the United States (U.S.) [1].
Creating a sustainable medical system for the growing
elderly population is a looming challenge for many of
these countries. Japan’s elderly already comprises of
25.0% (2014) of the nation’s population [2], with higher
percentages in some communities that are even further
along the aging curve. These communities have already
implemented measures that may prove to be a model of
care for others. Kaita, a rural area in Fukuoka prefecture
is one of these locations, with 34.2% of its 5,914 inhabitants
over 65 years of age (2014) [3].
In Japan, all citizens have medical care and long-term
care coverage under a universal health insurance system,
that consists of occupational insurance for salaried
workers (employees) and National Health Insurance
(NHI) for self-employed, including farmers and the
elderly [4]. To address the aging population with one of
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the lowest total fertility rates in the world (1.39 in 2010)
[4], the Japanese government introduced the Long-Term
Care Insurance (LTCI) system to supplement the exist-
ing universal health insurance and pension system in
2000 [4–7]. This system was implemented to promote
socialization of care with the slogan “Transitioning From
Care by Family to Care by Society” [4, 5]. Another goal
of the LTCI is to support organized community-based
integrated care [8, 9], especially for the increasing num-
ber of the frail elderly and home-bound patients with
medical and nursing needs [5–7].
LTCI supports care services, community-based ser-
vices, and in-facility services [4]. Although all primary
insured persons (over age 65) are candidates for care,
secondary insured persons (ages 40-65) diagnosed with
15 diseases (Alzheimer’s disease, stroke, end-stage can-
cer, etc.) can also utilize care services. Those under 40
are not eligible and are not required to pay the LTCI fee.
When insured persons need to use the LTCI, they
submit a request to the municipal government for their
primary physicians to assess and evaluate their physical
and mental status. A local Nursing Care Needs Certifica-
tion Board determines the eligibility and care needs level
for insured people using these results. Evaluated persons
are categorized as “rejected”, “care support level” 1 ~ 2,
and “care level” 1 ~ 5, which corresponds to benefit
eligibility ranging from $417 to $3005 per month in
2012 and 2013. Care services using allotted benefits are
coordinated by a care manager in discussion with the
insured person and his/her family [4–7].
The LTCI budget is derived from 50% tax (25% state,
12.5% prefecture, and 12.5% municipality) and 50%
insurance contribution from subscribers, and is con-
trolled by the municipal government (insurer). The
municipal government pays 90% and subscribers pay
10% for billed services. Insurance contributions to the
municipal government are deducted from the pension of
the primary insured person (ages 65 and older) and from
the public medical insurance premium for the secondary
insured person (ages 40 to 64) subscribers [4].
Although home care services and programs have also
been implemented in other countries [10–16], Zaitaku
(“staying at home” in Japanese) care is unique in that
primary care physicians lead home care teams consisting
of nurses, rehabilitation staff, pharmacists, medical aides
(helpers), care managers, and case managers using LTCI
and public medical insurance including national health
insurance (NHI) [8]. To be enrolled in Zaitaku care,
patients must be unable to get to outpatient clinic and
must reside within roughly 16 km of the hospital or
clinic that provides these services. They must pay a
monthly management fee to contract for medical care.
As part of this contract, physicians are required to see
patients once or twice per month depending on their
medical needs. Following enrollment in the program, a
visiting nurse triages the patient to determine whether a
physician (either the primary care physician or the
on-call physician at night or on weekends) is needed.
Primary care physicians care for a broad range of pa-
tients at home, from infants to elderly patients with
complex medical problems. Teams can provide services
such as phlebotomy, ultrasounds, fluid aspiration (from
abdomen, chest and knees), intravenous infusions, anti-
biotics, respiratory therapy, home oxygen therapy, phys-
ical therapy, occupational therapy, pharmacotherapy
education, and palliative care.
Dying at home was the tradition for many years in
Japan. Eighty three percent of the population died at
home in 1951. Current literature on end of life care
suggests that people still prefer to stay at home [17–
21], but more Japanese citizens die in health care facil-
ities (81.6% in 2003) than at home [8]. There are still
some roadblocks such as deficiencies in patient and
family knowledge regarding home care and support
systems for caregivers, but the biggest barrier may be
the lack of widespread medical systems that can
adequately support patients’ wishes to spend their last
days at home [22, 23].
With the aging population, it is essential that the
home care system is financially sustainable. Some re-
ports show that home care can generally save 19%-25.5%
of medical costs, but there are scant data to show that
there is a cost-benefit for home visits compared to
standard care [24–30]. For example, team-managed
home-based primary care costs are 6.8% higher at
6 months and 12.1% higher at 12 months more than
control [31]. End of life care, with completion of advance
directives and incorporating palliative care at home,
showed a 45% savings by reducing emergency admission
and hospitalizations [32–34], but other studies failed to
show that home palliative care service had positive cost
benefits overall [35, 36]. Most existing studies focus only
on nursing care costs, because medical costs are decided
by the conventional reimbursement system with public
medical insurance systems and/or medical insurance
companies. Therefore, in this report, we examined total
medical costs including medical and nursing care fee for
home visit care hoping to create a milestone for other
aging societies. We did not assess the family’s additional
cost- food, shelter, clothing, etc.
Although some studies assess medical costs at the end
of life comparing home-based and hospital-based pallia-
tive care [32–36], no study has specifically examined the
total medical costs of physician-led team home visit care
at the end of life compared to hospital care. This report
describes a cross-sectional study of medical costs for
physician-led team home visit care vs. in-hospital man-
agement at the end of life.
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Methods
Overview of study design
Kaita Hospital has an outpatient clinic and 96 inpatient
beds, located in Iizuka city, Fukuoka prefecture, Japan.
Seven supervising family medicine physicians (attend-
ings) and 3 family medicine residents provided inpatient
and outpatient services to patients and supervised a
physician-led team home visit (Zaitaku) care team in
2012 and 2013. After patients were enrolled in the
Zaitaku care with or without LTCI, care managers coor-
dinated their care services. The Zaitaku care team was
of standard composition: family medicine physicians,
nurses, care managers, and medical aides (home
helpers). Physical therapists, occupational therapists and
pharmacists were incorporated as needed. Team com-
munication occurred though meetings, internet commu-
nication tools, phone calls and fax.
Medical charts and total medical costs for medical and
nursing care of all patients who died at home with
Zaitaku care or in the hospital during the last 30 days of
life were analyzed as a cross-sectional study from Sep-
tember 2012 to August 2013 at Kaita hospital and home
care facilities.
Participants
Patient profiles were collected for Zaitaku and hospital
care during the period. The two groups were identified
by gender, whether they had cancer or dementia, usage
of opioids or IV fluids, oxygen requirements, and antibi-
otics treatment status (Table 1). Patients under Zaitaku
and hospital care were further divided into 3 groups de-
pending on the duration of home care before death
(short-term defined as 1 to 10 days, medium-term de-
fined as 11 to 29 days, and long term defined as more
than 30 days, Table 5) and sorted by factors using the
same methods as in Table 1.
Medical costs
Total medical costs (including public medical insurance
and LTCI) were claimed by the hospital or/and care fa-
cilities. This included medical fees under public insur-
ance, LTCI fees for services, nursing services, pharmacist
medication-management, medical aids, physical and oc-
cupational therapy with or without transportation fees.
Medical costs for physician services, tests, and medica-
tions were calculated as itemized treatments, which were
coded by the name of disease in a system similar to
ICD10, for reimbursement under the public medical in-
surance (Additional files 1 and 2). Episodic medical and
nursing fees for conditions such as severe decubitus ul-
cers, need for IV fluids, and palliation of end-stage can-
cer were covered by public medical insurance and other
care by LTCI system. Terminal care fees were claimed
when physicians diagnosed patients’ death at home and
visited more than twice within 14 days and/or within
24 h of their death. Medical contract fees were specific
for Zaitaku care, and mandated periodic physician home
visits periodically (usually twice a month), and covered
communication expenses, medical equipment and sim-
ple procedures such as collecting sputum samples and
simple dermatologic care [37]. For the purposes of
comparison, medical costs were calculated as daily rates
instead of the total cost for 30 days prior to death.
Currency conversion from Japanese yen to U.S. dollars
was performed by using the U.S. dollar equivalent rate
in 2015 (1U.S. dollar = 120 Japanese yen).
Total medical costs of patients utilizing Zaitaku and
hospital care were analyzed (Table 2) and compared
those two groups by factors (age, sex, cancer, dementia,
opioid use, infusion fluid, oxygen (Tables 1, 3, and 5).
Patients receiving hospital care were further divided into
two groups, depending on whether they had previously
received home visit care or not. Medical costs of hospital
care were compared after or without Zaitaku care
(Table 4). Total medical costs were compared with na-
tional average medical costs in Japan (Fig. 2, Additional
file 3) [38]. The medical costs of patients under Zaitaku
and hospital care of short (≦10 days), medium (11-
29days), long (≧30 days)-term periods were compared
(Table 6).







Age (mean ± SD) 80.7 ± 12.5 80.2 ± 9.5 0.571**
Gender 1.000*
Female (%, n) 39.4% (n = 13) 40.3% (n = 29)
Male (%, n) 60.6% (n = 20) 59.7% (n = 43)
Primary diagnosis (%, n)
Cancer 66.7% (n = 22) 45.8% (n = 33) 0.060*
Dementia 39.4% (n = 13) 40.3% (n = 29) 1.000*
Oxygen (%, n) 36.4% (n = 12) 72.2% (n = 52) 0.001*
Infusion fluid (%, n) 84.8% (n = 28) 94.4% (n = 68) 0.136*
Opioids (%, n) 42.4% (n = 14) 40.3% (n = 29) 0.834*
Antibiotics (%, n) 27.3% (n = 9) 40.3% (n = 29) 0.274*
*p-values were calculated using analysis of the Fisher’s exact test
**p-value was calculated using analysis of the Wilcoxon rank sum test
Table 2 Total medical costs of patients utilizing Zaitaku and
hospital care (US$/day)
Characteristics Zaitaku care Hospital care p-value
Total medical costs 371.2 (n = 33) 202.0 (n = 72) p = 0.492*
*p-value was calculated using analysis of the Wilcoxon rank sum test
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Relationship between medical costs and home visiting times
Medical costs and home visiting times were analyzed for
the different care term groups (Table 7, Fig. 1).
Statistical analyses
Values were expressed as the mean ± standard deviation
when the data were normally distributed data or the me-
dian ± interquartile range when the data did not follow a
normal distribution. Fisher’s exact test was used for the
categorical baseline variables of patient profiles, and the
non-parametric Wilcoxon rank sum test and Kruskal-
Wallis test were used for age analysis (Tables 1 and 5).
Medical costs were compared using the Wilcoxon rank
sum test (Tables 2, 3, 4, and 6). Propensity scores were
generated to estimate the probability of home visit care
or hospital care assignment by using binomial logistic
regression. The variables for estimating propensity
scores included age, sex, cancer, opioids, infusion fluid,
oxygen and dementia. A two-tailed p value <0.05 was
considered significant by the non-parametric Wilcoxon
rank sum test (Table 3). The comparison between
Zaitaku care with monthly fees or adjusted monthly fees
and hospital care were analyzed using multiple compari-
son (Bonferroni) methods (Table 6). Medical costs and
home visits numbers for Zaitaku were compared between
those groups using non-parametric Kruskal-Wallis test
(Table 7).




From September 2012 to August 2013, 34 patients died
at home under Zaitaku care, and 72 patients died
under hospital care. All patients completed their ad-
vance directives at the time of admission to either pro-
gram. For Zaitaku care patients, total medical costs
were calculated including public medical insurance,
LTCI and medication costs, except for one patient
whose LTCI costs could not be obtained. Among 33
patients who died under Zaitaku care, three patients
switched from hospital care to Zaitaku care (No. 8, 11,
29 of Additional files 1 and 2). One patient was hospi-
talized between days 4 to 8 before death (No.33,
Additional file 2). Among 72 patients who died under
hospitalized care, 17 patients had switched from Zai-
taku care. For patients who died in the hospital, total
cost for hospital care was obtained. The mean age was
80.7 years (range, 36-98 years) for Zaitaku care and
80.2 years (range, 51-98 years) for hospital care (p =
0.571, Table 1). Males comprised 60.6% of the Zaitaku
care group and 59.7% of the hospital care group (p =
1.000). Cancer patients represented 66.7% of the
Zaitaku care group and 45.8% of the hospital care
group (p = 0.060). There was no difference in the pro-
portion of dementia patients (p = 1.000), those on opi-
oids (p = 0.834), those receiving IV fluids (p = 0.136), or
those with antibiotic use (p = 0.274) in each group.
Oxygen was more frequently used in hospitalized pa-
tients compared with those receiving Zaitaku care (p <
0.01) (Table 1).
Comparison of medical costs within 30 days before dying
The medical cost of Zaitaku care and hospital care
within 30 days prior to death were calculated. The aver-
age medical cost for Zaitaku care (33 cases) was $371.2/
day. The average medical cost for hospital care (72
cases) was $202.0/day. Zaitaku care cost more than hos-
pital care, but the difference was not significant (p =
0.492, Table 2). To match patients in Zaitaku care and
hospitalized care, the propensity score method was used
to compare medical costs between matched patients
with Zaitaku care and hospitalized care. There was no
significant difference between those groups (p = 0.60,
Table 3).
Costs for hospital care after or without Zaitaku care
within 30 days of dying
The average total medical cost of hospital care for the
30 days preceding death was $202.0/day (72 cases,
Table 2). The average cost of hospital care without any
Zaitaku care (55 cases) was $202.2/day, and the cost of
hospital care after some Zaitaku care (17 cases) was
$200.8/day (Table 4, p = 0.952). Thus, there was no
significant difference in the medical costs with or with-
out some Zaitaku care preceding the hospital care at
final day of life.
Patient characteristics for short, medium, and long-term
periods
Patient characteristics of short (≦10 days), medium (11-
29days), long (≧30 days)-term periods were examined by
age, gender, diagnosis (cancer and/or dementia), oxygen,
Table 3 Medical costs of Zaitaku and hospital care by using
propensity score method (US$/day)
Characteristics Zaitaku care (n = 33) Hospital care (n = 33) p-value
Medical costs
median [Q1, Q3]
201.2 [151.8, 749.0] 188.2 [164.6, 229.3] 0.60*
*p-value was calculated using analysis of the binomial logistic regression
Table 4 Medical costs of hospital care after or without Zaitaku
care (US$/day)





Medical costs 200.8 202.2 0.952*
*p-value was calculated using analysis of the Wilcoxon rank sum test
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infusion fluid, opioids, and antibiotic use (Table 5). In both
Zaitaku and hospital care, age of the short-term group
was significantly younger than other groups (p = 0.024 at
Zaitaku care, p = 0.008 at hospitalized care) and used
opioids more than other groups (p = 0.303 at Zaitaku care,
p = 0.011 at hospitalized care). With the hospital care
group, short-term users had more cancer (p = 0.057) and
less dementia (p = 0.075), used less antibiotics (p = 0.022),
infusion fluid (p = 0.023). With the Zaitaku care group,
there was no difference diagnoses among those periods
(cancer:p = 1.000, dementia:p = 0.715), or use of antibiotics
(p = 0.595) and infusion fluids (p = 0.303).
Costs for different durations of Zaitaku and hospital care
within 30 days of dying
The average medical cost of Zaitaku care for short-term
was $868.0/day (9 cases), medium-term was $255.6/day
(7 cases), and long-term was $155.8/day (17 cases)
(Table 6). Short-term Zaitaku care costs were signifi-
cantly higher than medium-term care (Table 6, p < 0.01)
and medium-term care were significantly higher than
long-term care (Table 6, p < 0.05). Average medical costs
of Zaitaku care for more than 90 days was less ($131.0/
day) than the care of 30-90 days ($150.5/day, Additional
files 1, and 2). The average medical cost of hospital care
Fig. 1 Total cost of Zaitaku care at end of life. Horizontal axis shows the duration of Zaitaku care. Vertical axis shows the medical costs per day for
each patient. The patients are plotted by the shorter duration and the higher costs of Zaitaku care. Those data are shown in Additional file 1 and 2
Table 5 Baseline characteristics of patients utilizing Zaitaku and hospital care for short (≦10 days), medium (11-29days), long
(≧30 days)-term periods














Age (mean) 71.0 ± 15.5 82.3 ± 6.1 85.5 ± 10.3 0.024** 74.9 ± 10.7 83.8 ± 9.0 80.5 ± 8.8 0.008**
Gender 0.011* 0.529*
Female (%, n) 66.7% (n = 6) 14.3% (n = 1) 35.3% (n = 6) 46.2% (n = 6) 50.0% (n = 8) 34.9% (n = 15)
Male (%, n) 33.3% (n = 3) 85.7% (n = 6) 64.7% (n = 11) 53.8% (n = 7) 50.0% (n = 8) 65.1% (n = 28)
Diagnosis (%, n)
Cancer 66.7% (n = 6) 71.4% (n = 5) 64.7% (n = 11) 1.000* 76.9% (n = 10) 37.5% (n = 6) 39.5% (n = 17) 0.057*
Dementia 33.3% (n = 3) 28.6% (n = 2) 47.1% (n = 8) 0.715* 15.4% (n = 2) 56.2%(n = 9) 41.9% (n = 18) 0.075*
Oxygen (%, n) 33.3% (n = 3) 42.9% (n = 3) 35.3% (n = 6) 1.000* 61.5% (n = 8) 87.5% (n = 14) 69.8% (n = 30) 0.271*
Infusion fluid (%, n) 88.9% (n = 8) 71.4% (n = 5) 88.2% (n = 15) 0.675* 84.6% (n = 11) 87.5% (n = 14) 100.0% (n = 43) 0.023*
Opioids (%, n) 66.7% (n = 6) 28.6% (n = 2) 35.3% (n = 6) 0.303* 76.9% (n = 10) 37.5% (n = 6) 30.2% (n = 13) 0.011*
Antibiotics (%, n) 22.2% (n = 2) 42.9% (n = 3) 23.5% (n = 4) 0.595* 7.7% (n = 1) 43.8% (n = 7) 48.8% (n = 21) 0.022*
*p-values were calculated using analysis of the Fisher’s exact test
**p-value was calculated using analysis of the non-parametric Kruskal-Wallis test
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for short-term was $221.0/day (13 cases), medium-term
was $225.1/day (16 cases), and long-term was $187.4/
day (43 cases) (Table 6). Among those groups, medical
costs for shorter care was significantly higher (Table 6, p
= 0.004). The average medical costs of Zaitaku and hos-
pital care for short, medium, and long-term period were
compared (Table 6). Zaitaku care fees included the
monthly contract fee and the one-time terminal care fee
for the final day of life. With short-term care, Zaitaku
care was higher than that of hospital care (868.0 vs.
221.0 p < 0.001). With long-term care, Zaitaku care was
less than that of hospital care (155.8 vs. 187.4 p = 0.055).
To investigate the underlying cause for the higher
costs of short-term Zaitaku care the daily medical costs
with adjusted daily additional fees (divided care days
from the monthly contract fee and the one-time ter-
minal care fee for the final day of life) were calculated
(Table 6): $498.5/day (42.6% less with adjusted daily add-
itional fees) for short-term, and $238.5/day (6.7% less
with adjusted daily additional fees) for medium-term
(Additional files 1, and 2). Total average medical costs of
Zaitaku care within 30 days adjusting those fees is
$266.8 (28.2% less with adjusted daily additional fees). It
was 1.32 times higher than the cost of hospitalization at
the end of life, but not a significant difference (p =
0.3625, $266.8 vs. $202.0, Table 6).
The relationship between the number of physicians’
visits per day and medical costs were also examined
(Table 7). The numbers of visits provided for short-term
care was significantly higher than medium-term care
and longer care (p < 0.0001).
Discussion
Medical costs at the end of life pose serious concerns for
aging societies. In the U.S., 25.1% of medical insurance
costs are accrued in the last year of life [39]. In the U.K.,
approximately 20% of hospital bed days are utilized for
end-of-life care [40]. We showed that Zaitaku care cost
more than hospital care for short-term care (≦10 days)
(p < 0.01, Table 6), but Zaitaku care for long-term care
(≧30 days) might be associated with a 16.7% cost savings
compared with exclusively hospital care (p = 0.0549,
Table 6). The average duration of Zaitaku is 108.5 days.
Longer Zaitaku care more than 90 days generated less costs
($131.0/day) than the care of 30-90 days ($150.5/day,
Additional files 1, and 2).
The Japanese national average costs for hospital care is
$219.8/day at small hospitals with less than 200 beds,
$316.1/day at hospitals with more than 200 beds,
$381.4/day at public hospitals, and $537.7/day at univer-
sity hospitals in 2012 and 2013 (Fig. 2, Additional file 3)
[41]. The average medical cost in our hospital care even
at the end of life care was $202.0/day, that was lower
than at any public or university hospital in Japan. These
lower costs relate to our lower ratio of nurses to patients
Table 6 Total medical costs of patients utilizing Zaitaku with monthly fees, adjusted daily fees and hospital care for 30 days
* p-values were calculated using multiple comparison (Bonferroni) method
**p-value was calculated using analysis of the Wilcoxon rank sum test
***Monthly fees include the monthly contract fee and the one-time terminal care fee for the final day of life
****Adjusted fees include the adjusted daily contract fee and the one-time terminal daily care fee for the final day of life














1.48 (n = 9) 0.50 (n = 7) 0.27 (n = 17) p < 0.0001*
*p-value was calculated using analysis of the the non-parametric
Kruskal-Wallis test
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(1 to 10) and the fact that most of the patients had ad-
vanced care planning. The medical costs in our hospital
were lower than the average in Japan, and the cost of
Zaitaku care for more than 30 days at the end of life
may also be found to be less costly (Table 6).
We found that short-term Zaitaku physician-led home
visit care for end of life was costly (Table 6, Fig. 1,
Additional files 1, and 2). Some contributing factors may
be the monthly contract fee for the Zaitaku team, one-
time terminal care fee for the final day of life care at
home specifically for Zaitaku care from the Japanese
Ministry of Health, Labor and Welfare (JMHLW),
monthly payments for care services, and costs of home
care equipment including home oxygen. Our Zaitaku
care facility is recognized as a superior hospital by the
JMHLW, with more than 3 physicians who provide more
than 10 emergency home visits and oversee more than 4
patient deaths at home per year. To assess the medical
costs for Zaitaku (physician-led home visits team) care,
total medical costs, the daily terminal care fee, and daily
medical care contract fee, which are specific to the Zai-
taku care by the JMHLW, were all calculated. The total
average medical cost of Zaitaku care with adjusted daily
fees was 28.2% less than monthly fees (Table 6) and the
cost without monthly fees was 14% less than hospital care
within 30 days of the last day (Additional files 1 and 2).
Frequent visits for Zaitaku care in the short term may
result in higher costs than in the longer term (Table 7),
because every physician-led home visit was paid from
public insurance. The findings of high costs of Zaitaku
care in the short period are valid. It is likely that subse-
quent work will identify differences between patients
cared for primarily in hospital and those at home – not
just relative to diagnosis (since the diagnoses between
the two groups were similar) – but likely related to other
as yet unidentified factors. As more patients survive se-
vere illnesses that previously would have resulted in
rapid deaths, we will need to identify how to appropri-
ately care for them in the post-hospitalization period in
a compassionate and cost-effective fashion.
Our certified family physician group examined medical
costs of a physician-led home visit team care during the last
30 days of life. In our practice, the same group of primary
care physicians provides medical care with palliative mea-
sures at the end of life both at home and at the hospital.
The fact that we are able to compare these two groups of
patients cared for by one consistent group of physician
providers is a strength of this study. Physicians learned pal-
liative care from lectures and workshops for cancer patients
and end of life care at a 2-day program of the Palliative
Care Emphasis program on symptom management and
Assessment for Continuous medical Education (PEACE)
project [41] guided by experts from the U.S. and the U.K.
Physicians and nurses offer the palliative care supporting
patients and their families with Zaitaku team members.
Some patients did not use LTCI (Additional file 2, case
No. 22, 28, 33), which lowered the total cost of their
medical care. The costs for food and nursing care by
family members or volunteers for patients receiving
Zaitaku care were not included, which may decrease the
overall costs compared to the hospital care group.
For example, the medical cost for one patient with
amyotrophic lateral sclerosis (Additional file 2, No. 33)
was the lowest in the Zaitaku care group. That patient’s
family supported the patient for a long time, and they did
not want to utilize care services.
Fig. 2 Medical costs of Zaitaku and hospital care vs. average hospital care in Japan. Comparing the medical costs of Zaitaku and hospital care at
the end of life (30 days) at Kaita hospital and the average medical costs in Japanese hospitals. The costs of Zaitaku care (left light gray column,
Kaita hospital, long term, $155.8) and hospital care (left dark gray column, Kaita hospital:$187.4; white columns, Japanese average <200 beds:
$219.8, Japanese average ≧200 beds: $316.1, Japanese average of public hospital: $381.4, Japanese average of university hospital: $537.7, ref. 38,
Additional file 3) were shown
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One significant benefit of Zaitaku care is that it is an
interdisciplinary, team-based approach. Various mem-
bers of the team help each other to prevent provider
burnout [29, 31]. The Zaitaku team can provide essential
physical and emotional support to caregivers by valuing
their efforts and helping alleviate caregiver fatigue. This
can additionally elevate both the patients’ and families’
satisfaction at the end of life [21, 31]. The comprehen-
sive team approach also makes problem-solving easier
compared to teams with only physicians or nurses.
Those benefits help fulfill patients’ and their caregivers’
wishes to spend their last days at home.
Although there was no significant difference between
the groups in regards to sex or age, there were more
cancer patients in the Zaitaku care group compared with
the hospital care (p = 0.06, Table 1). Patients with cancer
have significant health care needs and may need com-
prehensive assessment of prognosis to appropriately de-
termine the level of care as they plan their end of life
care at their home. Their families might support their
wishes given their limited remaining time [42].
Our study has limitations. (1) The study is a pilot and
thus is small; (2) all costs are not accounted for because
we didn’t assess the non-medical costs to the families;
(3) the time analysis was limited and focused on the last
30 days of care; (4) many social and insurance issues that
support Zaitaku care are unique to Japan, but could be
adapted in other countries; (5) the reimbursement fee
schedule for medical costs is adjusted every two years by
JMHLW; therefore, medical costs may change in the
future; (6) this study examines cross-sectional data from
one incorporated medical institution in a rural area of
Japan and the cost benefits of Zaitaku care may be
increased when compared with lower categorized care
clinics and hospitals. These results can inform evidence
based policy making for private and/or public medical
insurance systems. Cost is important but other factors
such as patient and family satisfaction and quality of
care also should be investigated further.
Conclusions
Although the Zaitaku physician-led home visit team care
costs more than hospital care for short-term care (less than
10 days), costs may be lower than hospital care for long-
term care (more than 30 days) at the end of life. Medical
costs at a Zaitaku care at long-term was 82.1% lower than
that care at short-term ($155.8 vs. $868.0, p < 0.05). Medical
costs of Zaitaku care in the long-term (more than 30 days)
were 16.7% lower than that of hospital care ($155.8 vs.
$187.4, p = 0.055). To fulfil patients’ wishes to spend the
end of life at home and promote a community-based inte-
grated care system, physician-led home visit team care is a
promising option for medical care with possible cost
benefits when implemented earlier in the end-of-life period.
This report is the first study evaluating the medical costs of
the physician-led home visits team care at the end of life care.
Additional files
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